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3Introduction
It may seem unbelievable; but with a pop-
ulation of only nine million people, Sweden has
had a profound impact on medical and biolog-
ical science in the world. For instance, in the
1940s Arne Tiselius discovered electrophoresis,
a method of protein analysis with great impor-
tance and practicality used in medical and bio-
logical research today. In 1950, Inge Edler and
Hellmuth Hertz devised echocardiography, a
non-invasive method for examining the heart.
This medical technology revolutionized car-
diovascular diagnostics throughout the world.
Also, such products as the dialysis machine, the
world famous ulcer medicine omeprazole
(Losec®), and the acid pump inhibitor
esomeprazole magnesium (Nexium®) are  all
worldwide contributions adding to Sweden’s
scientific clout. (“Swedish Inventions and
Discoveries”) 
In the 21st century, a high priority is
placed on biotechnology as a means to foster
economic growth and scientific discovery.
While the world usually looks toward the United
States, the United Kingdom, Germany, and
France to take the lead within this biotechno-
logical race, should Sweden be ignored as one
of the favorites?  The answer is “No.” Currently,
the Swedish biotechnology industry enjoys high
international status. It comprises more than
200 companies, ranking fourth in Europe in
terms of total number of biotech companies and
ninth in the world. (“Biotechnology and
Pharmaceuticals in Sweden,” p. 1) Thus, despite
Sweden’s small population, it has still managed
to contribute substantially to the field of
biotechnology. With such success, it is no sur-
prise that Sweden’s intent is to support the
emergence of its new sector consisting of small-
er, more innovative biotech companies.
However, although the Swedish biotechnology
industry has great potential, many of these
smaller companies are currently stuck in the
start-up phases of development, slowing down
the Swedish biotech engine. Employing strate-
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4gies that lead to better early seed financing and
strengthened ties between industry and acade-
mia will prove helpful in overcoming this prob-
lem. Only then will Sweden be able to make it
through the final lap. 
I begin this article by highlighting the
importance of the biotechnology industry in
Sweden. Next, I provide statistical evidence
illustrating the industry’s problems with early
seed financing and the need for strengthened
ties between industry and academia. Finally, I
discuss strategies to help alleviate these prob-
lems and conclude with thoughts on the future
of this potential industrial powerhouse.
What Is Biotechnology?
According to Sandstrom and Norgren,
biotechnology is defined as the application of
science and technology to living organisms in
order to alter living or non-living materials for
the production of knowledge, goods, and serv-
ices. (Sandstrom and Norgren, p. 9) The
Swedish biotechnology companies that produce
knowledge, goods, and services are divided
among six industrial sectors. Modern biotech-
nology is used mainly in the pharmaceuti-
cal/medical subsector of the industry where
more than 50 percent of the companies and
employees in the biotech industry are found.
This subsector aids in drug discovery, develop-
ment, diagnostics, and medical technology.
Also, the subsectors of bioproduction and
biotech tools and supplies have shown impres-
sive scientific advancements in recent years. For
example, BioInvent International AB, a firm in
the bioproduction subsector, produces biolog-
ic molecules and microorganisms such as 
monoclonal antibodies and fusion proteins for
use by other biotech firms. In addition,
Pyrosequencing, a firm in the biotech tools and
supplies subsector, produces equipment such
as DNA-sequencing instruments for use by
biotech companies and universities. Finally, sci-
entific applications of the subsectors of envi-
ronmental biotechnology, agrobiotechnology,
and functional food and feed result in products
for plant improvement, waste disposal, and
increased nutrition, respectively. (Sandstrom
and Norgren, pp. 51–52)
Why Is Biotechnology Important to
Sweden?
The Applications of Biotechnology
Speaking at a 2003 conference in
Washington, DC, Jan Eliasson, Swedish ambas-
sador to the U.S., stated, “Biotech is promising
not only because it can help develop our indus-
tries but also because biotech can contribute
solutions to many of society’s challenges.”
(Eliasson) With increasing knowledge in
genomics and proteomics, biotechnology com-
panies are finding useful applications for
improving the quality of life. For example, the
health care sector can enjoy the development
of new drugs, diagnostic tools, and treatments.
In 2001 the Swedish company Biovitrum was
founded as a spin-off from the Pharmacia
Corporation. With approximately 575 employ-
ees, it is one of the larger biotech firms in
Sweden and focuses on various stages of drug
discovery for prevalent metabolic diseases such
as obesity, type 2 diabetes, and certain types of
cancers. (“Biovitrum”) Biotechnology also can
improve the use of biologic processes for devel-
oping food with increased nutritional value. The
biotech company Biogaia uses the micro-
organism Lactobacillus Reuteri as a probiotic
(food that contains living microorganisms) for
humans and animals in hopes that it will have
beneficial health effects in the gastrointestinal
tract. Finally, biotechnology can help improve
the environment with new methods for soil
treatment, waste disposal, and water treatment.
For example, ANOX AB develops methods for
testing levels of toxic substances and micro-
organisms in sewage. After analysis, bacterial
strains may be used from dunghills and swamps
to transform waste products into methane gas.
Thus, much of the driving force behind the
biotechnology industry stems from the indus-
try’s trans-sectoral nature. (Sandstrom and
Norgren, pp. 53–54)
Economic Growth
In addition to a wide range of applications,
a second reason biotech is important for
Sweden is the industry’s promising rate of
 
5growth.1 From 1997 to 2001, the total number
of Swedish biotech companies in all sectors of
the industry increased by 36 percent (from 135
to 183). In addition, the total number of
employees in the industry increased over this
period from 2,677 to 3,975. Annual turnover,
the ratio of company sales to inventory, is
another indicator of economic growth. All sub-
sectors except one within the industry showed
growth in annual turnover between the years
1997 and 2000. The pharmaceutical sector of
biotech in Sweden grew by 31 percent and envi-
ronmental biotechnology grew by 100 percent,
while the remaining sectors of bioproduction,
biotech tools and supplies, and functional food
and feed enjoyed a growth in annual turnover
between 60 percent and 80 percent.
Agrobiotechnology, however, showed a 
13 percent decrease. (Sandstrom and Norgren,
pp. 65–68) 
A Strong Science Base
In addition to its strong economic growth
in the biotech sectors, Sweden also has a repu-
tation for possessing a strong science base. To
date, eight Swedes have received the Nobel
Prize in physiology and medicine. Sweden also
has received recent attention — even notoriety
— from its pioneering research on adult and
embryonic stem cells. Finally, Sweden ranks
third in Europe (after Switzerland and
Denmark) on a per capita basis in the total
number of biotechnology and applied microbi-
ology scientific publications. (Bergstrand, p. 5) 
A strong science base is a necessity for
achieving a successful biotech industry. The
higher the quality of research and knowledge
that a country produces, the more likely it is
that the country will attract prominent scien-
tists and collaborate with successful science
companies. The data compiled by VINNOVA (see
footnote 1) reveals that the Swedish share of the
world’s total number of scientific publications
increased in five of seven life science fields from
1987 to 2001, with the fields of immunology,
neuroscience/behavior, and biochemistry/
biophysics showing the three largest totals. 
Signs of Trouble for Swedish
Biotechnology
Indicators of Economic Trouble2
All evidence points to recent growth in the
Swedish biotechnology industry. The number
of companies, the number of employees, and
the rate of turnover all have increased.
However, the continued economic growth of an
industry through the launching of new prod-
ucts and services is a costly process. In order to
maintain financial strength, stability, and
growth, these industrial endeavors must be
financed through the infusion of profits and not
by loans or continued venture capital (VC). But,
according to two measures of economic
strength, the equity/assets ratio and net prof-
its/losses ratio, the situation is somewhat dis-
appointing.
The equity/assets ratio is one measure of
financial strength. However, an equity/assets
ratio between 30 percent and 50 percent indi-
cates that the owners of the company have
funded only 30 percent to 50 percent of the
assets, leaving more than half of the company’s
assets funded by debt. Therefore, the company
is highly leveraged and is a riskier investment
for outside creditors. Equity/assets ratios with-
in this range were observed for all sectors of the
biotech industry in Sweden between 1997 and
2000. (Sandstrom and Norgren, pp. 67) Another
way of analyzing this situation is by using the
debt/equity ratio. Using the equity/assets ratio
of 30 to 50 percent as a baseline, this translates
into a debt/equity ratio between 1 and 2.333,
indicating that between 50 percent and 70 per-
cent of the company’s assets are financed 
by debt. This is further evidence that compa-
nies within the Swedish biotech industry are
highly leveraged. 
In addition, the trend of growing net loss-
es does not present an image of a prosperous
industry. At the sectoral level, net losses were
seen in four of six sectors between 1998 and
2001, with only the agrobiotechnology and
1The biotech companies described in this section are
small and medium-sized with up to 500 employees. Much
of the statistical data in this section was derived from a
recent analysis by VINNOVA, the Swedish agency for inno-
vation systems.
2The author would like to thank Dr. Parveen Gupta for
assistance with this section.
6environmental biotech sectors showing net
profits. Net losses over time combined with
high and increasing debt/equity ratios indicate
that the activities of many companies within
the biotech industry have been financed by the
infusion of VC and not by net profits. However,
with so many companies dipping into the same
pool of financial resources, companies are now
being halted in their start-up phases of devel-
opment. (Sandstrom and Norgren, pp. 67–71)
With many old and new companies relying
heavily on seed financing, the question is
whether sufficient capital will be available to
support the development of Sweden’s promis-
ing biotech industry. 
Lack of Venture Capital
A look at Sweden’s VC industry will help
determine whether sufficient capital currently
exists. Between 1995 and 2000, Sweden enjoyed
a fast growing VC industry, and VC firms spe-
cializing in biotech and life sciences frequent-
ly provided start-up and expansion capital to the
industry. However, this trend has been chang-
ing. As outlined in Table 1, the percentage of
investments in both the seed and start-up phas-
es decreased from 2000 to 2001; investments 
in the later, more stable expanding phase 
of companies increased dramatically. (“The
Development …”)
In addition, a survey by the Swedish
Venture Capital and Private Equity Association
(SVCA) and the Swedish Business Development
Agency (NUTEK) conducted every quarter since
the first financial quarter of 2001 reveals some
other interesting trends within the VC indus-
try. The most dramatic trend is the decline in
the number of seed-phase investments: the
number of investments decreased for six quar-
ters in a row, from 27 seed investments total-
ing 125 million Swedish krona (SEK) (c. $15.6
billon) during the first quarter of 2001 to only
four seed investments totaling 13 million SEK
during the second quarter of 2002. (Berggren)
Thus, while the total amount of financing 
available is shrinking, the distribution of financ-
ing is changing as well. According to a
PricewaterhouseCoopers MoneyTree survey, the
U.S. also experienced a dry spell in VC activity
during 2001, with such activity in the VC sec-
tor falling from approximately $106 billion total
investments made in 2000 to only about $40
billion in 2001. Furthermore, most investments
were made in the later stages of company devel-
opment. The declining U.S. trend also charac-
terized VC investments within the life sciences,
which totaled $6.9 billion in 2000 and $5.3 bil-
lion in 2001. Thus, although this dry spell is not
unique to Sweden, the country must still find
a way to address this problem in order to help
its biotechnology industry grow. It is significant
that during the first six months of 2002, sever-
al industries, including information technolo-
gies (39 percent), communications (26 per-
cent), and Internet technology (19 percent),
have attracted larger percentages of total invest-
ments available than the biotech industry (18
percent), thus creating increased competition
for financial resources. (“The Development…”) 
Considered altogether, this evidence
reflects a problem for small Swedish biotech
companies. Johan Lembke, Senior Project
Manager, Science and Technology, Embassy of
Sweden, eloquently summarized the senti-
ments of Swedes and Americans: “The provision
Table 1
Distribution of Investments Made by the Swedish Venture Capital Industry
Phase of Company Development 2000 (%) 2001 (%)
Seed 14.3 9.3
Start-up 49.6 33.0
Expansion 30.1 46.6
Replacement 1.1 4.4
Buyout 4.0 6.7
Source: “MoneyTree™ Survey.” 
7of and access to early-stage funding is becom-
ing an even more difficult task in a time when
promise and products, rather than promise
alone, often are favored.” (Lembke, p. 3) Many
venture capitalists are taking fewer risks and
investing in later stages of company develop-
ment, making it difficult for new companies to
get started. Sweden must address this problem
in order for the industry to continue to grow.
Lack of Early Public Seed Financing
Public seed financing is available to
biotech companies from government agencies
such as NUTEK and the Swedish Innovation
Centre (SIC). However, in a questionnaire sent
in June 2000 to the managing directors of 139
biotech companies, criticism was voiced regard-
ing the support of this current government
funding system. Namely, the responding man-
aging directors complained that government
agencies such as NUTEK and SIC have become
prone to taking fewer risks and are acting more
like the venture capitalists discussed previous-
ly who are demanding later-stage, lower risk
options for investment. (Backlund et al., pp.
45–46) This criticism is not without merit.
Starting in 2002, Industrifonden, another gov-
ernment agency, was to take over much of the
early seed financing of NUTEK. However, few
investments have come out of this collabora-
tion. In addition, NUTEK and other government
agencies can only finance half of the total
investment needed to start a company, with the
other half being matched by non-governmen-
tal investors. Thus, the amount of public early
seed financing available to biotech companies
is small. (Sandstrom and Norgren, p. 77)
Citation Trends
Scientific research articles are an impor-
tant resource for biotech companies. These
companies draw on research, most of which is
done at the academic level, in order to develop
new ideas and products. Thus, with university
researchers authoring 96 percent of life science
articles, employing strategies to help strength-
en the ties between industry and academia
might prove beneficial to the success of small-
er biotech companies. 
One indication of the quality of published
articles is the extent to which they are cited in
later articles. However, over the last twenty
years, there has been a decline in the relative
citation level of Swedish research articles com-
pared to the relative citation level of research
done in other countries. Between 1981 and
2001, the relative citation levels for Swedish
articles within the life science fields of neuro-
science/behavior and biochemistry/biophysics
have fallen below the global average (indicated
as 1.0 in Figures 1 and 2). The relative citation
level for Swedish articles within the life science
field of cell/developmental biology has 
also decreased. On the other hand, for biotech-
nology/applied microbiology, molecular biolo-
gy/genetics, and microbiology, the citation
trend is increasing beyond the global average
while within the field of immunology there is
no clear trend. (Sandstrom and Norgen, p. 22)
However, Sweden publishes the largest per-
centage of its total number of research articles
from the fields of neuroscience/behavior and
biochemistry/biophysics. Thus, what becomes
disheartening is that within these two fields,
Sweden is losing ground in citation levels rel-
ative to several other countries despite Sweden’s
beginning at a higher-than-global average.
Figure 1 shows that within the field of neuro-
science/behavior, Germany, Canada, the U.K.,
Switzerland, and the U.S. all have now sur-
passed Sweden in relative citation levels, while
Sweden has actually dropped below 
the global average. The situation is similar 
in the field of biochemistry/biophysics, as
Figure 2 shows. 
Some argue that these decreasing trends
are inconsequential for the Swedish biotech-
nology industry. Although the number of
Sweden’s publications and relative citation lev-
els in the field of biotechnology/applied micro-
biology is on the rise, this field covers only a
small part of the total publication volume. The
significance of this overall decreasing citation
trend, though, is that biotech companies do not
rely on knowledge from just one life science dis-
cipline. Rather, they rely heavily on knowledge
in many fields in order to generate ideas that
will enable them to take off and move beyond
the start-up phase. For example, Biovitrum is
one of Europe’s largest biotech companies; it
 
8Figure 1
Relative Citation Levels for Articles within the Field of Neuroscience/ 
Behavior, 1981–1997 (World Index=1)*
Source: Sandstrom, Anna and Lennart Norgren. 
* The values listed along the y-axis indicate whether a country's citation level is above, below, or at the world
average citation level shown as 1.0.
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Figure 2
Relative Citation Levels for Articles within the Field of Biochemistry/ 
Biophysics, 1981–1997 (World Index=1)*
Source: Sandstrom, Anna and Lennart Norgren. 
* The values listed along the y-axis indicate whether a country's citation level is above, below, or at the world
average citation level shown as 1.0.
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9produces recombinant protein products and
plasma products. In order to research and
develop such products, scientific knowledge
from the fields of molecular biology/genetics,
biochemistry, and immunology is used.
(“Biovitrum”) 
Strategies to Improve the Biotech
Industry
Increasing Venture Capital
Investments
Sweden already has begun to employ sev-
eral methods to try to overcome the lack of VC
available to small biotech companies. For exam-
ple, the largest Nordic VC company, HealthCap,
with locations in both Sweden and Switzerland,
has created new funds of 3 billion SEK. The
HealthCap fund will invest globally in pharma-
ceutical, biotechnology, and medical technolo-
gy companies. It remains to be seen how such
a new fund will be distributed among the stages
of company development, but the new fund
promises to give small Swedish biotech com-
panies a chance to move beyond the seed and
start-up phases. (Sandstrom and Norgren, 
p. 80)
Creandum is a new Nordic VC firm created
by the Sixth Swedish National Pension Fund and
Skandia Liv. Creandum is one of the few Nordic
venture capital companies to focus its invest-
ments exclusively on early-stage technology. The
fund will manage approximately 400 million
SEK. Creandum admits that there is almost no
early-stage venture capital available in Sweden
today. It also acknowledges that there are com-
panies with roots in universities and science parks
that need competent early-stage investors with a
long-term commitment to help them get off the
ground. In a 2003 press release, Creandum
described its excitement to be one of those play-
ers. For its first investment opportunity,
Creandum plans to make 10 to 15 investments in
scientific sectors where there are opportunities
to create internationally competitive companies,
where there are companies that have the poten-
tial for dramatic growth, and where there are
companies that service markets of considerable
size. With these criteria, Creandum is a good can-
didate to help several companies within the
biotech industry. (“Creandum”)
Increasing Government
Investments
Swedish government agencies have heard
the complaints voiced by many small and medi-
um-sized biotech companies and have begun to
employ methods to increase the amount of gov-
ernment investment. For example, NUTEK,
ALMI Business Partner, and VINNOVA initiated
a contest in 2002 where the most interesting
new technology-based business enterprise
could win grants. Of the 429 contenders, 
20 received grants of 300,000 SEK each, with
three of the winners having innovative ideas in
the field of biotechnology. Although the num-
ber is small, it nonetheless represents Sweden’s
acknowledgement of the lack of government
investment and its attempt to make some
improvement. (Sandstrom and Norgren, pp.
77–78) In addition, seed funds are being
launched at universities, such as the KTH 
Seed Capital Fund at the Royal Institute 
of Technology. This fund was created by
Industrifondem, W Capital Management, SEB
Foretagsinvest and KTH Holding. The fund’s
investments, totaling 127 million SEK, will help
support high-tech companies in the early phas-
es of their development. “KTH is the leading
institute of technology in the Nordic region
today,” says Jan Sundberg, chairman of KTH
Seed Capital. “KTH has in recent years spun off
a number of companies with an aggregate value
exceeding 20 billion SEK. By creating KTH
Seed Capital, we hope to develop the potential
that resides in KTH.” (“KTH Seed Capital Gets
MSEK 127,” p. 1)
Strengthening Ties between
Industry and Academia
When universities have completed high
quality research, this knowledge must be trans-
ferred to industry quickly and efficiently. A
weakness in this transfer process can slow the
cycle and keep biotech companies in the start-
up phases of development for much longer than
desirable. In order to improve the transfer of
knowledge, Sweden already has certain initia-
tives in place. 
To stimulate the development of small and
medium-sized biotech companies, Sweden has
created science and technology parks with the
purpose of facilitating technology transfer
between industry and academia. The majority
of the Swedish science and technology parks are
linked to universities and organized in the
Swedepark association. Swedepark is a non-
profit association founded in 1989 to offer a
supportive environment for the establishment
of new firms, product development, and coop-
eration between companies and academia.
Swedepark currently has 31 members from
both established science and technology parks
and parks in the planning stages. Spin-off com-
panies in the early stages of development typi-
cally set up camp within these parks in order to
have access to new knowledge and educated
personnel. (“Swedepark…”) An investigation
performed by Linkoping University shows that
companies located within these parks have a
tendency to grow faster than other companies
in the same business. (Backlund et al.) 
The Swedish Institute for Food and
Biotechnology (SIK) was founded in 1996 when
the Biotechnology Research Foundation (SBF)
merged with the Institute for Food and
Research. Approximately 120 companies, main-
ly from the food sector and the biotechnology
sector, belong to the SIK. The SIK offers many
services to its company members, such as a
pilot program in which researchers from
biotech companies are stationed at academic
institutions. The researchers devote half their
time to company activity and half to academic
activity. This arrangement gives the biotech
industry access to new knowledge through an
established pipeline and allows a larger outflow
of ideas from academia into the industry. The
knowledge gained can be particularly beneficial
to smaller companies in early stages of devel-
opment, giving them a better chance to produce
new and innovative products. (Backlund et al.,
pp. 97–99)
Strategies to Improve Swedish
Biotechnology
Building Business Competence
Of the methods Sweden is beginning to
employ, many involve the creation of new VC
funds. However, this alone may not be sufficient
to shift the focus from late-stage to early-stage
investment. Because of Sweden’s increasing
number of biotech start-ups, there is fierce
competition for early investments. Thus, the
problem of lack of VC requires the attention not
only of the VC industry but also the attention
of the biotech companies.
In order to attract investment and move
out of the start-up phase, Swedish biotech com-
panies must prove to VC investors that they pos-
sess both clear-cut technologic and commer-
cial advantages. They can accomplish this task
by showing investors that they are leaders with-
in their fields of research and can produce prod-
ucts with sustainable, long-term growth. Also,
these biotech companies must show their
investors that they have good internal organi-
zation, stability, and scientific experience.
(“Elements to Consider When Seeking Capital”)
Without good company management and per-
sonnel, investors will not provide companies
with financing. Thus, scientists in biotech com-
panies need to have expertise in the business
world. Biotech companies must be aware that
investors wish to gain a profit just as much as
the company does. Thus, it is important for
companies to market themselves as best as they
can by showing investors how they will make
their money grow with products that can reach
a large market. The solution to overcoming a
lack of venture capital is two-sided, one that
requires the contributions of both the VC indus-
try and biotech industry.
The same strategy holds true in order to
gain more public seed financing. Increasing the
amount of financial investment made by gov-
ernment agencies is not enough to help biotech
companies move past their early stages of devel-
opment. Respondents to the 2000 VINNOVA
survey also mentioned the need for competent
business advice and support. Thus, in addition
to providing increased financial assistance, the
Swedish government can help biotech compa-
nies become skilled in business practices.
(Backlund et al., p. 46) 
A 1996 international study conducted by
Bo Carlsson, Professor of Industrial Economics
at Case Western Reserve University, revealed
that start-up biomedical/biotech companies
located in the state of Ohio (with 11 million
inhabitants and 422 firms) grew much faster,
provided twice as many jobs, and generated
10
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much more total revenue ($15.0 billion vs. 
$6.1 billion) than similar start-up firms 
in Sweden (with 9 million inhabitants and 
230 firms). Carlsson proposed that the reason
Ohio biotech companies were more successful
was that they possessed more managerial com-
petence. Firms in Ohio were able to recruit
experienced management, were superior at
commercialization, had better access to financ-
ing (especially VC), had better links to scientif-
ic advisors, and enjoyed faster technology trans-
fer between industry and academia. Although
both Ohio and Sweden both possessed strong
science bases, Sweden had too few venture cap-
italists and weaker managerial skills. Based on
this evidence, Swedish government agencies
may be well advised to develop databases of indi-
viduals with specific competencies regarding
business development in the biotechnology
field. Individuals within such a database could
provide business management and networking
skills and help companies seek out VC funds
and other possible investors. Another option is
for government agencies to develop workshops
where scientific personnel within biotech com-
panies can learn about entrepreneurship and
business theory and practices. The key is com-
bining capital investments with business skills.
New seed capital funds can continue to devel-
op, but without a knowledge of business,
biotech companies have a lower chance of mov-
ing past the start-up phases of their develop-
ment. 
Strengthening the Scientific
Knowledge Base
According to Tim Corless, Senior Associate
Director for Science and Technology Ventures
at Columbia University, “The main job of a uni-
versity is to do research. But then, this research
should be transferred to society as efficiently as
possible so that the money the university
research generates for the industry can go back
into the university.” This statement provides
the premise for a strong plan of action to help
strengthen ties between the Swedish biotech
industry and Swedish academia. Swedish uni-
versities must first begin to generate more sci-
entific knowledge with the hope that this
knowledge will in turn create novel ideas from
which the biotech industry can work.
There are several ways that Swedish uni-
versities and secondary schools can strengthen
their scientific knowledge base. First, it is
increasingly necessary for Swedish secondary
and higher education science programs to 
have a greater multidisciplinary approach.
Biotechnology transcends rigid, established
delineations between various science fields.
(Magnusson, p. 30) For example, companies in
the tools and supplies sector of biotechnology
sell to customers within the scientific areas of
bioseparation, biomolecular analysis, biosen-
sors, genomics, bioinformatics, and fermenta-
tion equipment. To use some specific examples
of Swedish firms, Amersham Biosciences AB
provides systems and products for research into
genes and proteins. The firm Biacore develops
tools for biomolecular interactions. The firm
Gyros produces microlaboratories in the shape
of a compact disc, and the firm Pyrosequencing
produces DNA-sequencing instruments. Initial
development of all these products relied on
combining fundamental knowledge from chem-
istry, biology, physics, and engineering.
Refinement of the products required expertise
in the fields of software development, optics,
mechanics, and electronics. (Sandstrom and
Norgren, p. 52) 
Another method by which the scientific
foundation of Swedish research can be
strengthened is offering better incentives to
Swedish scientists to return home after doing
research abroad. Sweden’s Knut and Alice
Wallenberg Foundation argues that a country
should encourage young researchers to work
abroad for the opportunity to gain valuable
knowledge and expertise. (“Plugging the Brain
Drain”) However, the Foundation’s director,
Erna Möller, realizes that better incentives can
be given to return home. For example, the
Foundation currently pays for Swedish scien-
tists to work at U.S. institutions such as the
Massachusetts Institute of Technology.
However, if the researchers return to Sweden,
the Foundation also pays for laboratory con-
struction and donates millions of krona in
equipment so that researchers have the best
work environment they need to succeed.
(“Plugging the Brain Drain”) In addition to sub-
sidizing education and equipment, Sweden
12
might also consider providing tax breaks for
these individuals as another incentive.
(Magnusson, p. 27)
At a recent conference entitled “Sweden
and the United States: Excellence in
Biotechnology,” it was suggested that Swedish
universities could enhance the development of
the biotech industry if universities were to edu-
cate not only students but also the public.
Several voices at the conference called for acad-
emia to play a larger role in explaining new
technologies and scientific information to the
public. A constructive dialogue between
researchers and the public (patients, physicians,
journalists, etc.) could help the Swedish biotech
industry reach its full potential. For example,
across Europe many consumers have rejected
genetically modified foods, and public concern
over these products remains high. A European
opinion poll published by the European
Commission in December 2001 showed that
94.6 percent of EU citizens wanted the right to
choose, 85.9 percent wanted to know more
before eating genetically modified foods, and
70.9 percent did not want to eat genetically
modified foods at all. In November 2000, the
Nordic Industrial Fund carried out a survey in
Denmark, Finland, Norway, and Sweden 
on genetically modified foods. The Nordic
Industrial Fund found that when a product
involved genetic modification, the public
viewed this idea negatively, using words such
as “unhealthy” and “uncertainty.” (“What
Europeans Think about GMOs”) These statis-
tics suggest that if the public is uninformed on
ethical and research issues, the growth of the
biotechnology industry may be cut short. If
researchers take the time to explain new tech-
nology to the public and how these technolo-
gies can benefit their lives, there is a better
chance for the industry to reach its potential. 
Strengthening the Transfer of
Knowledge from University to
Industry
In addition to the generation of knowl-
edge, competitiveness and the potential for eco-
nomic growth depend on transferring this
knowledge to industry quickly and efficiently.
A weakness in the transfer can slow the cycle
previously discussed and keep biotech compa-
nies in the start-up phases of development for
much longer than desired. The following sug-
gestions may help Sweden to strengthen the
transfer of information from university to
industry. 
Large companies such as AstraZeneca
have dominated the field of biotechnology in
the past. However, if these larger pharmaceuti-
cal and biotechnology companies invest more
money into university research, smaller spin-
off biotech companies may be born and more
effectively cross the threshold into later stages
of development with continued support from
these “mentors.” Syngenta is one example of
such a spin-off company. After the merger of
Astra and Zeneca in 1999, Novartis agribusiness
and AstraZeneca’s agrochemicals division
merged to form Syngenta, which has become a
successful agrobiotech company. (“Syngenta”)
Finally, Swedish universities might con-
sider requiring undergraduate and graduate
students to enroll in courses on entrepreneur-
ship, specifically entrepreneurship within the
life sciences and related fields. Within these
courses, students can learn ways to finance a
newly started company, leadership and negoti-
ation tactics, and the rules and regulations that
exist within the industry. 
Future Prospects
In this article I have analyzed the
strengths and weaknesses of Sweden’s biotech-
nology industry and have offered several sug-
gestions for its improvement. Small and medi-
um-sized Swedish biotechnology companies
face an uncertain future. These companies need
to devise a plan to cross the threshold into later
stages of development in order to enjoy vigor-
ous and sustained growth. There is no doubt
that, if more of these companies were able to
leave the start-up phases of development, there
would then be stronger opportunity for eco-
nomic growth in the Swedish biotechnology
industry. Lena Torell, President of the Swedish
Academy of Engineering Sciences, stressed that
once the industry enjoys a period of sustained
success, its future growth will lie in its ability
to foster even newer links between previously
separate fields. Coined “The New Industrial
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Paradigm” (Torell),  the biotech industry will
be driven to foster strong ties with the emerg-
ing fields of nanotechnology, information tech-
nology, materials technology, computing, arti-
ficial intelligence, and software. From these
partnerships a range of new products, applica-
tions, and services will be generated with a great
potential for success. 
Sweden is well positioned to be a world
leader in this emerging paradigm and to reap
significant rewards. But first, small biotech
companies must cross the boundary into later
phases of development so that the whole indus-
try can finish the final lap of the biotech race.
By fine-tuning the trouble spots currently ham-
pering Sweden’s biotech industry, Sweden has
the potential for attaining high international
status in future scientific endeavors.
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